ARCH Venture Partners XII, L.P. — SEC insider filings
SEC reporting owner CIK 1979765. 17 insider filings on record with FilingPulse; latest filed 2026-10-19.
Transaction summary — filings shown
Covers all 17 filings on record, filed 2023-09-20 to 2026-10-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 26 legs across 13 filings — 13,645,286 shares, $129,289,987 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 34.
- Largest priced transaction: purchase of 1,432,224 shares @ $18.00 ($25,780,032) in Metsera, Inc., filed 2025-02-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Metsera, Inc. (MTSR) | Director, 10% owner | 2 | 2 legs · 2,222,222 sh · $39,999,996 | — | 9 |
| Neumora Therapeutics, Inc. (NMRA) | 10% owner | 9 | 20 legs · 3,922,764 sh · $36,430,001 | — | 12 |
| Prime Medicine, Inc. (PRME) | 10% owner | 2 | 2 legs · 6,230,300 sh · $29,999,990 | — | — |
| Seaport Therapeutics, Inc. (SPTX) | 10% owner | 1 | 1 leg · 1,100,000 sh · $19,800,000 | — | 4 |
| CITY THERAPEUTICS, INC. (CTY) | 10% owner | 2 | 1 leg · 170,000 sh · $3,060,000 | — | 6 |
| Rapport Therapeutics, Inc. (RAPP) | 10% owner | 1 | — | — | 3 |
Insider filings — ARCH Venture Partners XII, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-19 | 4 | CITY THERAPEUTICS, INC. (CTY) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Conversion (C): 3,294,900 · Conversion (C): 5,482,309 · Conversion (C): 2,027,006 · Purchase (P): 170,000 @ $18 · Conversion (C): 3,000,000 (derivative) @ $0 · Conversion (C): 4,991,633 (derivative) @ $0 · +1 more | EDGAR |
| 2026-10-15 | 3 | CITY THERAPEUTICS, INC. (CTY) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Holdings only — no transactions reported | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN | Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Metsera, Inc. (MTSR) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 8,313,680 | EDGAR |
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, BYBEE CLINTON | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-08-01 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P. | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2025-02-03 | 4 | Metsera, Inc. (MTSR) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Conversion (C): 16,006,949 · Conversion (C): 7,523,682 · Purchase (P): 1,432,224 @ $18 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 more | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN | Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P. | Purchase (P): 3,200,000 @ $6.25 | EDGAR |
| 2023-12-12 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, BYBEE CLINTON | Other (J): 703,061 · Other (J): 1,176,593 | EDGAR |
| 2023-11-15 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 31,653 @ $11.75 · Purchase (P): 3,357 @ $11.98 | EDGAR |
| 2023-11-13 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 69,127 @ $10.78 · Purchase (P): 23,124 @ $11.79 · Purchase (P): 31,079 @ $10.53 · Purchase (P): 11,844 @ $11.37 · Purchase (P): 5,431 @ $11.75 | EDGAR |
| 2023-11-07 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 22,420 @ $11.38 · Purchase (P): 43,082 @ $11.55 · Purchase (P): 30,192 @ $11.50 | EDGAR |
| 2023-09-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 16,841 @ $13.06 · Purchase (P): 25,110 @ $13.69 · Purchase (P): 34,560 @ $13.98 | EDGAR |
| 2023-09-27 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 34,000 @ $11.73 · Purchase (P): 24,504 @ $12.31 | EDGAR |
| 2023-09-25 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 40,000 @ $11.14 · Purchase (P): 30,773 @ $10.80 · Purchase (P): 29,967 @ $11.65 | EDGAR |
| 2023-09-20 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, BYBEE CLINTON | Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2022-04-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1979765 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs